Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (7538)	12/18/2002 4:08:18 PM
From: Sam Citron	Read Replies (2) \| Respond to of 52153

All patients will eventually fail Chemo and Rit. Please elaborate.

To: Vector1 who wrote (7538)	12/18/2002 5:08:29 PM
From: ewolf	Respond to of 52153

I don't think you're missing anything. Bex market will be an evolving process. The drug has to prove itself with more usage. They're conducting trials to compare efficacy. The manufacturing has yet to be certified. It won't be on the market for at least five months. Still a case of what you believe will happen. I thought it would have dropped to the threes at least on turn down. I'm sure approval for marketing will add a more significant amount than today but it's anyone's guess what the price of the stock will be at that moment in time.

To: Vector1 who wrote (7538)	12/18/2002 6:44:42 PM
From: dalroi	Read Replies (1) \| Respond to of 52153

V1 require coordination between an oncologist and a nuclear medicine specialist dont think thats a problem they've to coordinate already lots of things like when to give chemo when to irradiate etc, shouldnt be a problem cheers S